Join today and have your say! It’s FREE!

We will not release or resell your information to third parties without your permission.

Please Try Again

By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

Please Try Again

Password Hint : {{passwordHint}}

Remember me

Forgot Password?

News Focus

LQWD Technologies Lightning Network Infrastructure Surpasses 1 Million Global Transactions (click to learn more)

Bullboard - Stock Discussion Forum COSCIENS Biopharma Inc T.CSCI

Alternate Symbol(s): CSCI

Healthcare Biotechnology

COSCIENS Biopharma Inc., formerly Aeterna Zentaris Inc., is a specialty biopharmaceutical company engaged in the development and commercialization of a diverse portfolio of pharmaceutical and diagnostic products, including those focused on areas of unmet medical need. Its lead product, macimorelin (Macrilen; Ghryvelin), is an oral test indicated for the diagnosis of adult growth hormone... see more

Add To Watchlist

Bullboard (TSX:CSCI)

View:

Post by prophetoffactzon Aug 11, 2024 2:04pm

Avenanthramide pill

Avenanthramide was the reason Gilles wanted to join CZO originally. More recently, in a December 2022 news release Gilles stated: "...our avenanthramide program and could be the most significant ...more

152

Discussion

Post by prophetoffactzon Aug 11, 2024 12:19pm

New Diagnostic Licensing Deal:

In July 2023, in a news release, AEZS said "...based upon our active outreach and discussions, we expect to secure an alternate development and commercialization partner for Macrilen® ...more

126

Pharmaceutical Tech Co Reports 2.7X Revenue Growth Year-Over-Year at US $24 Million

posted Nov 21, 2024 9:00am by Innocan Pharma Corp

"Our strong operational and financial momentum continued throughout 2024 and now in the third quarter, we again demonstrated solid financial results. We are pleased to report nine consecutive quarters of continuous revenue growth. Our online platform continues to perform exceptionally well, contributing to our strong nine-month revenue growth of 174% YoY ...read more

Comment by prophetoffactzon Aug 11, 2024 11:23am

RE:PGX Scale-up:

What percentage of the yeast beta glucan immune booster market could CSCI take with a potentially clearly superior source of yeast beta glucan further enhanced by PGX? CSCI and partner could have a ...more

Discussion

Post by prophetoffactzon Aug 11, 2024 10:52am

PGX Scale-up:

Tomorrow will be 15 weeks since the scale-up of PGX to 50L was said "almost completed" after three trial runs. Three trial runs would allow a judgement concerning the repeatability of ...more

126

Discussion

Post by Hopeforthebeston Aug 09, 2024 11:42am

RE: PGX-YBG

proph said "Based on the average timeline from submission to the journal Biomaterials to publishing the comprehensive article on PGX-YBG/Fibrosis could be published within the next 30 days" ...more

Post by prophetoffactzon Aug 09, 2024 9:14am

PGX-YBG

Based on the average timeline from submission to the journal Biomaterials to publishing the comprehensive article on PGX-YBG/Fibrosis could be published within the next 30 days. In the October Small ...more

The Market Update

< Previous bulletin

Next bulletin >

A daily snapshot of everything
from market open to close.

< Previous

Next >

Dealroom for high-potential pre-IPO opportunities

Become a member today, It's free!

Bullboard - Stock Discussion Forum COSCIENS Biopharma Inc T.CSCI

Alternate Symbol(s): CSCI

Bullboard (TSX:CSCI)

Avenanthramide pill

New Diagnostic Licensing Deal:

Pharmaceutical Tech Co Reports 2.7X Revenue Growth Year-Over-Year at US $24 Million

RE:PGX Scale-up:

PGX Scale-up:

RE: PGX-YBG

PGX-YBG

Featured News Links

Discover Options Trading Strategies to Minimize your Tax Burden

Become a member today, It's free!

Sign In

Send my password

Become a member today, It's free!

Bullboard - Stock Discussion Forum COSCIENS Biopharma Inc T.CSCI

Alternate Symbol(s): CSCI

Join the community and start posting on the bullboards today. It's free.

Create a portfolio watchlist today. It's free.

Bullboard (TSX:CSCI)

Featured News Links